Tinea corporis pharmaceutical market refers to the special medical needs relating to Tinea Corporis, a common dermatophyte infection referred to as ringworm. The purpose of this market is to offer reliable and efficient pharmaceutical treatment for Tinea corporis which is basically a superficial fungal infection of the skin. This condition is characterized by itchy red rings on different parts of one’s body like on the necks calling for immediate attention since they are so uncomfortable.
The Pharmaceutical Market on Tinea Corporis is primarily based upon antifungal medications that provide both topical and systemic treatments regarding several etiologic agent’s fungi mostly belonging to Trichophyton or Microsporum species. For mild to moderate forms, topical antifungal creams, lotions or powders aim at eradicating surface fungi invading skin layers. Clotrimazole, miconazole or terbinafine are usually the main active components in these creams that hinder further proliferation.
Severe and chronic cases may necessitate use of systemic antifungal drugs including oral tablets or capsules which contain fluconazole or itraconazole as some of them. As such, these systemic therapies operate inside an individual’s system with respect to infections from ringworm which makes them complete therapeutically significant. Each case requires different treatment options; therefore, the importance of the Pharmaceutical Market on Tinea Corporis cannot be overemphasized.
Also, patient education and preventive measures should be emphasized on in pharmaceutical solutions for tinea corporis market. In order to prevent recurrence of tinea corporis proper hygiene practices, not sharing personal items as well as maintaining dry clean skin environment are essential. Nowadays, many pharma companies run awareness campaigns targeting early detection and prompt treatment.
Market challenges facing Pharmaceutical Tinea Corporis cases can be due to misdiagnosis or self-treatment thereby delaying appropriate pharmaceutical interventions. It reiterates that accurate diagnosis can only be achieved through consultation with health care professionals, who will then be able to plot individual medication plans for this challenge. Also, new antifungal medications and delivery methods are being developed to improve treatment efficiencies and patient compliance.
These are the reasons why the Pharmaceutical Market on Tinea Corporis is vital owing to its global nature; it can occur in any age-group or demographic globally. The prevalence of Tinea corporis depends on climate, living conditions and personal hygiene practices which varies between populations hence there are pharmaceutical solutions for diverse populations among different geographical areas.
Because the market is evolving continuous emphasis is placed on improving tolerability and convenience of antifungal treatments for tinea corporis. Consequently, developing soothing moisturizing formulations that contain other active ingredients such as antifungal agents aim at making patients comfortable during their course of therapy. This goes along with call by pharma industry towards patient centric approach where instead of focusing only on efficiency it also includes patient experience factors during medication process.
The Tinea corporis market is anticipated to reach USD 18.05 Billion by 2030 at 3.10% CAGR during the forecast period 2022-2030.Tinea corporis is a fungal infection that is caused by tinea rubrum, trichophyton mentagrophytes and epidermophyton floccosum fungi. This fungal infection mainly occurs in humid climatic condition. It is also known as ringworm infection. Tinea corporis infection occurs mostly on arms, legs or can also occur on different parts of body. Tinea corporis is contagious infection which can spread from one person to other hence it is important not to share towel, flannels, bathmats with another person.
Global tinea corporis market is segmented into drug type, diagnosis, treatment and end-users. Tinea corporis market on basis of drug types is segmented into antifungals, steroids and anti-infective combinations.
Based on diagnosis tinea corporis market is segmented into physical exam, imaging tests. Imaging test is further sub-segmented into wood lamp (black light) examination, microscopy using potassium hydroxide (KOH), fungal culture, skin biopsy and others.
Based on treatment tinea corporis market is segmented into antifungal shampoos, antifungal creams, drugs and others. On basis of end-user market is further segmented into hospital pharmacies, drug stores, online pharmacies, dermatology hospitals, medical research centres, academic institutes others.\
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The tinea corporis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of the tinea corporis market.
The European tinea corporis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The tinea corporis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The tinea corporis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Global Tinea Corporis Market Share (%), by Region, 2017
Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon
Geographically, the America holds the highest market share for tinea corporis market and the reason being many market players are engaged in development of new drug product innovation, and as this infection is more prone to humid climatic condition there is an increasing prevalence of fungal infection in this region. Whereas increasing awareness of fungal disease and rising healthcare expenditure by the government are some of the factors responsible for growth of market in this region
Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of fungal infection, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region.
Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of fungal infection, changing lifestyle, increase in population, increasing healthcare expenditure by government are some of the factor responsible for market growth in this region.
Tinea Corporis Market Key players
Some of the key players in the global tinea corporis market are
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)